UK markets close in 6 hours 58 minutes

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
1.4200-0.1800 (-11.25%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 20.13M
Enterprise value 20.24M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.51
Price/book (mrq)0.68
Enterprise value/revenue 0.51
Enterprise value/EBITDA 8.14

Trading information

Stock price history

Beta (5Y monthly) 0.17
52-week change 3-16.47%
S&P500 52-week change 323.57%
52-week high 32.3600
52-week low 31.4200
50-day moving average 31.8164
200-day moving average 31.8290

Share statistics

Avg vol (3-month) 310.05k
Avg vol (10-day) 38.19k
Shares outstanding 514.18M
Implied shares outstanding 614.18M
Float 88.02M
% held by insiders 144.06%
% held by institutions 115.57%
Shares short (15 Apr 2024) 417.31k
Short ratio (15 Apr 2024) 41.61
Short % of float (15 Apr 2024) 40.22%
Short % of shares outstanding (15 Apr 2024) 40.12%
Shares short (prior month 15 Mar 2024) 420.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -15.88%
Operating margin (ttm)-30.31%

Management effectiveness

Return on assets (ttm)-4.44%
Return on equity (ttm)-19.41%

Income statement

Revenue (ttm)39.55M
Revenue per share (ttm)2.77
Quarterly revenue growth (yoy)2.50%
Gross profit (ttm)N/A
EBITDA -1.27M
Net income avi to common (ttm)-6.28M
Diluted EPS (ttm)-0.4400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)18.32M
Total cash per share (mrq)1.29
Total debt (mrq)18.43M
Total debt/equity (mrq)62.98%
Current ratio (mrq)1.28
Book value per share (mrq)2.10

Cash flow statement

Operating cash flow (ttm)6.09M
Levered free cash flow (ttm)9.33M